Wedbush Issues Positive Estimate for KNSA Earnings

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) – Equities research analysts at Wedbush increased their Q1 2025 earnings per share estimates for shares of Kiniksa Pharmaceuticals in a research report issued to clients and investors on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn $0.10 per share for the quarter, up from their prior estimate of $0.09. Wedbush has a “Outperform” rating and a $34.00 price objective on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS and FY2025 earnings at $0.56 EPS.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million during the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm’s quarterly revenue was up 67.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.20) EPS.

Other research analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Evercore ISI increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $36.60.

Kiniksa Pharmaceuticals Stock Down 2.3 %

Shares of KNSA opened at $18.39 on Thursday. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15. The stock has a market capitalization of $1.33 billion, a P/E ratio of -131.35 and a beta of 0.29. The company has a 50 day moving average of $20.85 and a 200-day moving average of $23.24.

Insiders Place Their Bets

In other news, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. This trade represents a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the transaction, the chief operating officer now owns 88,975 shares of the company’s stock, valued at $1,622,904. This represents a 13.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,092 shares of company stock valued at $471,609. 54.57% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Large investors have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. increased its position in Kiniksa Pharmaceuticals by 1.9% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock worth $3,947,000 after buying an additional 3,673 shares during the period. Nordea Investment Management AB grew its position in shares of Kiniksa Pharmaceuticals by 4.4% during the 4th quarter. Nordea Investment Management AB now owns 194,883 shares of the company’s stock worth $3,818,000 after purchasing an additional 8,257 shares in the last quarter. JPMorgan Chase & Co. bought a new position in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $4,997,000. Franklin Resources Inc. raised its position in shares of Kiniksa Pharmaceuticals by 1.7% in the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after buying an additional 1,100 shares in the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of Kiniksa Pharmaceuticals by 62.2% in the third quarter. XTX Topco Ltd now owns 27,302 shares of the company’s stock valued at $682,000 after buying an additional 10,474 shares during the period. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.